business buildings

InControl Medical Introduces Attain at CES 2019

InControl Medical is proud to announce that Attain, the most advanced over-the-counter device available to treat male and female incontinence and the logical first choice for treatment, will be shown at the 2019 Consumer Electronics Show (CES, January 8-11, Las Vegas Sands, Halls A-D – 43569). According to Herschel “Buzz” Peddicord, InControl’s founder and CEO, “This revolutionary medical device is designed to help treat the approximately 87 million people in the U.S. suffering with stress, urge, or mixed urinary incontinence, and/or bowel incontinence. Attain provides muscle stimulation, visual biofeedback, and a guided exercise program to solve incontinence at the source — the muscle level. Attain’s regular self-treatment program, in the privacy of one’s home, eliminates the need for pads, meds, surgery or diapers.” Read more.

Source: Business Wire, January 8, 2019

Magnetic Stimulation Restores Bladder Control in Paralyzed Men

Patients with spinal cord injuries report that in addition to paralysis the lack of bladder control is one of the most troubling issues. At University of California Los Angeles, researchers have shown that they were able to restore significant bladder control to five men that suffered through spinal cord injuries years prior to treatment. The researchers used transcutaneous magnetic spinal cord stimulation as their technique, delivering pulses of focused magnetic fields to the site of the injuries. Similar technology was just cleared in the United States to treat obsessive compulsive disorder. Read more.

Source: Medgadget, August 22, 2018

Finding Freedom and Eliminating Stigma

My Story – Submitted by: Waldo

This story was originally published in the Danish magazine Vertel.  You can access the original story and photos here: https://www.medireva.nl/wp-content/uploads/MEDIREVA-Vertel-lente-versie.pdf

Here is the author’s English translation, which he has asked that we share with you.

Dear reader,
I would like to share my personal story with you. I want to contribute to the elimination of the stigma and the taboo around incontinence. Continue reading

product approval

ProvenMed, wins MIT Arab Startup competition Award 2018

North African start-up, ProvenMed, has been named startup winner of the MIT Arab Startup competition 11th edition Award.  ProvenMed Co-Founder & CEO, Souheil Guessoum received the award at the ceremony chaired by the chair of the board of MIT Enterprise Forum Pan Arab, Hala Fadel. Promoted by MIT Enterprise Forum, the Arab Startup competition Awards aim to create an ecosystem based on the most outstanding startups from across the Arab countries. In addition to demonstration of innovation and a viable business model, winners are selected based on their contribution to advancing sustainability, active social responsibility engagement and participation in Arab projects and partnerships.  The 11th edition competition took place in Sultanate Oman on 19th of April 2018 and was supported by Community Jameel, a founding partner for 10 consecutive years. As a local support and engagement in the Sultanate of Oman, strategic partners this year include Riyada, the competition’s governmental backbone, and Omantel, the key contributor and supporter. Regionally, partners also include Zain Group, the competition’s digital partner.  ProvenMed, based in Tunis, was founded in 2017 and currently at the commercialization stage of its flagship innovative product ActivGo™ for men. Read more.

Source: Zawya, April 24, 2018

bladder retraining timed intervals

Prostate Operation That’s Done Via Your WRIST Can Cut Threat of Incontinence

THE PATIENT. About eight years ago, I started needing the loo frequently at night. I put up with it at first, but it gradually got worse — at one point I needed to go five or six times a night. My GP told me to avoid alcohol and caffeine as these irritate the bladder, but this didn’t make a great difference and my symptoms continued to worsen.  By last year, I was getting up for the loo in the night so often it left me feeling tired during the day.  My GP suspected I had an enlarged prostate so referred me to a urologist. A few weeks later, I underwent various tests, including one where a machine measures the speed of your urine flow.  Read more.

Source: Daily Mail, August 7, 2017

 

doctor male discussion

Uromedica Wins CMS Coverage for ProAct Continence Therapy Device

Uromedica said today it won a reimbursement code from the Centers for Medicaid and Medicare Services for its ProAct adjustable continence therapy for men, and that it launched the device in the US.  The ProAct system has FDA approval and is indicated for treating adult men with stress incontinence from intrinsic sphincter deficiency of at least 12 months following radical prostatectomy or TURP who have failed ot respond to conservative therapy, the Plymouth, Minn.-based company said. “The issuance of these codes will allow Uromedica to deliver its safe and effective therapy to improve the quality of life for men struggling with Stress Urinary Incontinence,” prez & CEO Tim Cook said in a press release. Read more.

Source: MassDevice Today, July 12, 2017

cancer

Prostate Cancer Patients Treated with Brachytherapy Retain Urinary, Bowel Quality

Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a study.  While patients reported a decline in these quality of life measures immediately after brachytherapy, they achieved a full recovery within six months. Brachytherapy involves inserting radioactive seeds in or near tumor to kill it.  The research, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was published in the Journal of Radiation Oncology, Biology, Physics.  “This study reinforces the position of Cesium 131 as an effective, patient-friendly treatment for localized prostate cancer,” Bill Cavanagh, chief scientific officer of the brachytherapy company IsoRay, said in a news release. “This is especially important as multiple studies are emerging that strongly suggest that the inclusion of brachytherapy must be considered for the treatment of high-risk prostate cancer – the toughest localized prostate cancer to cure.”  Read more.

Source: Prostate Cancer News Today, May 4, 2017

doctor male discussion

U.S. Guidelines Relax Opposition to Prostate Cancer Screening

An influential physician task force backed by the U.S. government is softening its opposition to routine prostate cancer screening.  In proposed guidelines released today, the U.S. Preventive Services Task Force advised men aged 55 to 69 to discuss the pros and cons of screening with their doctors rather than avoiding it altogether. The task force continued to recommend against a blood test for prostate specific antigen (PSA) in men 70 and older, concluding the potential harms of routine screening still outweigh the benefits for this age group. Since the last guidelines came out in 2012, new evidence has emerged suggesting that PSA tests may help lower the odds that tumors spread to other parts of the body or prove fatal for men aged 55 to 69, said task force chair Dr. Kirsten Bibbins-Domingo, a researcher at the University of California, San Francisco. New evidence also suggests it’s becoming more common for doctors to skip aggressive treatments like surgery or radiation for men with low-risk prostate tumors in favor of doing periodic tests to see if tumors grow, an approach known as active surveillance. Read more.

Source: Reuters, April 11, 2017

bladder retraining timed intervals

Hatch Medical to Broker Innovative Male Urinary Incontinence Device

Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced today that it has entered into an agreement with MUCOM, L.L.C. to broker the sale or license of its patented male urinary incontinence device MUI Comfort™. MUI Comfort™ is an integrated external collection system that meets the needs of a growing demographic that is coping with the consequences of stress, urge, and overflow incontinence. This innovative technology is differentiated from competing products by providing a complete solution that addresses both functional and psychological aspects associated with male urinary incontinence.  Read more.

Source: Yahoo Finance! February 16, 2017

medical research

Cytori Pivotal ADRESU Incontinence Trial Hits 50% Enrollment Milestone

Cytori Therapeutics, Inc. (CYTX) today announced that over half of 45 patients in the ADRESU trial in Japan have been enrolled and treated. ADRESU is a late phase, investigator-initiated Japanese clinical trial to study the efficacy and safety of Cytori Cell TherapyTM in men with stress urinary incontinence after prostatic intervention for prostate cancer or benign prostatic hypertrophy. Read more.

Source: Yahoo! Finance, December 14, 2016